Page 129 - Let them speak Towards a patient reported outcome measure set for
P. 129
PROs emerging from focus groups and interviews
22. FDA. Guidance for industry: patient-reported outcome measures: use in medical product
development to support labeling claims: draft guidance. Health and Quality of Life Outcomes.
2006;4:1-20.
23. Van Remmerden M, Hoogland L, Mous S, Dierckx B, Coesmans M, Moll H, et al. Growing up
with fragile X syndrome: concerns and care needs of young adult patients and their parents.
Journal of Autism and Developmental Disorders. 2020;50:2174-87.
24. Both P, ten Holt L, Mous S, Patist J, Rietman A, Dieleman G, et al. Tuberous sclerosis complex:
concerns and needs of patients and parents from the transitional period to adulthood. Epilepsy
& Behavior. 2018;83:13-21.
25. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common
sense to hard science. BMC medicine. 2011;9(1):1-12.
26. Basch E, Torda P, Adams K. Standards for patient-reported outcome–based performance
measures. Jama. 2013;310(2):139-40.
27. Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, et al. Pharmacologic
treatment of Rett syndrome with glatiramer acetate. Pediatric neurology. 2016;61:51-7.
28. Compendium P. Guide To Patient Involvement In Rare Disease Therapy Development. https://
everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-
COMPLETE-GUIDE-Rev.pdf2022.
29. Agency EM. Patient experience data in medicines development and regulatory decision-making.
https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-patient-experience-data-
medicines-development-regulatory-decision-making#documents-section2022.
30. Administration USFaD. FDA Patient-Focused Drug Development Guidance Series for
Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and
Regulatory Decision Making. https://www.fda.gov/drugs/development-approval-process-
drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-
patients-voice-medical2024.
31. PROMs Repository [Available from: https://erica-rd.eu/work-packages/patient-centred-
research/proms-repository/.
32. Maia N, Nabais Sá MJ, Melo-Pires M, de Brouwer AP, Jorge P. Intellectual disability genomics:
current state, pitfalls and future challenges. BMC genomics. 2021;22(1):1-17.
33. Frueh JS, Press DZ, Sanders JS. Diagnosis and workup of intellectual disability in adults:
suggested strategies for the adult neurologist. Neurology: Clinical Practice. 2021;11(6):534-
40.
34. Müller AR, van Silfhout NY, den Hollander B, Kampman DH, Bakkum L, Brands MM, et al.
Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials
in genetic neurodevelopmental disorders and intellectual disability. Therapeutic Advances in
Rare Disease. 2024;5:26330040241245721.
35. van Silfhout NY, van Muilekom MM, van Karnebeek CD, Daams J, Haverman L, van Eeghen AM.
Patient reported outcomes used in clinical trials and core outcome sets for individuals with
genetic intellectual disability: a scoping review. Journal of Neurodevelopmental Disorders. J
Neurodev Disord. 2025;17(1):43.
36. Terwee CB, Ahmed S, Alhasani R, Alonso J, Bartlett SJ, Chaplin JE, et al. Comparable Real-
World Patient-Reported Outcomes Data Across Health Conditions, Settings, and Countries:
The PROMIS International Collaboration. NEJM Catalyst Innovations in Care Delivery.
2024;5(9):CAT. 24.0045.
37. van Silfhout NY, van Muilekom MM, van Karnebeek CD, Haverman L, van Eeghen AM. PROs for
RARE: protocol for development of a core patient reported outcome set for individuals with
genetic intellectual disability. Orphanet Journal of Rare Diseases. 2024;19(1):1-9.
38. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):
a 32-item checklist for interviews and focus groups. International journal for quality in health
care. 2007;19(6):349-57.
39. Carlsen B, Glenton C. What about N? A methodological study of sample-size reporting in focus
group studies. BMC medical research methodology. 2011;11(1):26.
40. Temme B, Bikker A, Leeflang C, Groep B. Leidraad groepsbijeenkomsten: B&A Groep; 1999.
41. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101.
42. Varpio L, Ajjawi R, Monrouxe LV, O’Brien BC, Rees CE. Shedding the cobra effect: problematising
thematic emergence, triangulation, saturation and member checking. Medical education.
2017;51(1):40-50.
5
127
